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Purpose: To evaluate the cytotoxicity of varying doses of Bevacizumab on corneal endothelial cells in the presence of a
range of concentrations of vascular endothelial growth factor (VEGF). Bevacizumab, a drug widely used in the treatment
of  neovascular  glaucoma  neutralizes  all  isoforms  of  VEGF  and  ameliorates  neovascularization  after  intracameral
administration. However, the safety of intracameral administration of Bevacizumab and dose–dependent toxicity on
corneal endothelial cells has not been established.
Methods: Bovine corneal endothelial (BCE) cells were treated with VEGF (50 ng/ml) and/or Bevacizumab (0.1–2 mg/
ml) for 72 h. Cell proliferation was measured with the water soluble tetrazolium salts (WST-1) assay. Morphological
changes were recorded by bright-field microscopy of cells. Cytotoxicity in response to Bevacizumab was evaluated by
trypan blue exclusion, as well as annexin V/propidium iodide (PI) staining.
Results: Bevacizumab was not cytotoxic at the concentrations tested and the percentage of Bevacizumab-treated cells
staining positively for both PI and Annexin V was less than 1%. The anti-proliferative effects of Bevacizumab on BCE
cells were dose-dependent; a dose of 1.5 mg/ml or 2 mg/ml produced a 33% (p=0.005) or 47% (p=0.001) decrease in cell
proliferation compared to controls. Similar results were obtained in cells treated with a combination of Bevacizumab and
VEGF. VEGF (50 ng/ml) had no significant effect on cell proliferation compared to controls. Morphology of cells was
unchanged after treatment with Bevacizumab and/or VEGF compared to controls.
Conclusions: Bevacizumab was safe and not toxic to BCE cells at concentrations commonly used in clinical practice.
Bevacizumab, a full-length, humanized, anti- vascular
endothelial growth factor (VEGF) monoclonal antibody has
shown  promising  success  in  the  treatment  of  age-related
macular  degeneration,  choroidal  neovascularization  and
proliferative diabetic retinopathy [1-3]. Topical Bevacizumab
is used in early bleb failure after trabeculectomy, corneal
neovascularization  after  penetrating  keratoplasty  and
progressive  corneal  neovascularization  resistant  to
conventional  therapy  [4-6].  In  addition,  Bevacizumab
effectively  inhibits  iris  neovascularization  in  neovascular
glaucoma after intracameral administration [7,8].
However, the safety of intracameral administration of
Bevacizumab  and  dose-dependent  toxicity  on  corneal
endothelial cells have not been established. Toxicity to the
corneal  endothelial  cells  can  lead  to  loss  of  corneal
transparency and consequential blindness.
We  evaluated  the  cytotoxicity  of  varying  doses  of
Bevacizumab on corneal endothelial cells independently, as
well  as  in  association  with  VEGF  in  vitro.  Varying
concentrations  of  VEGF  were  used  to  mimic  aqueous
dynamics of neovascular glaucoma.
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METHODS
Cell culture: Bovine corneal endothelial (BCE) cells were
purchased from ATCC (Manassas, VA) and plated according
to the manufacturer’s protocol. The stock cell cultures were
maintained in T-75 flasks in Dulbecco Minimum Essential
Medium (DMEM; Invitrogen, Carlsbad, CA), supplemented
with 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis,
MO)  containing  100  mg/ml  penicillin  and  100  mg/ml  of
streptomycin (Invitrogen) at 37 °C in a 95% air and 5% CO2
incubator.  BCE  cells  were  treated  with  different
concentrations of human vascular endothelial growth factor
(0–100 ng/ml; VEGF165; Pepro Tech, Rocky Hill, NJ) and/or
0.1–2 mg/ml Bevacizumab (Avastin®; Genentech, South San
Francisco,  CA),  a  recombinant  humanized  monoclonal
antibody that inhibits the biologic activity of human VEGF
(Pepro Tech), for 72 h.
Cell cytotoxicity:
Trypan  blue  exclusion  assay—Cytotoxicity  was
evaluated by trypan blue exclusion assays. To test whether our
treatment with Bevacizumab at the doses and time points
measured was cytotoxic, we performed trypan blue staining
using an automated cell counter. Parallel experiments with
cell proliferation assays were set up in 6-well dishes by plating
10,000 cells/well. Cells were allowed initially to attach for 24
h. The cells were treated similarly as cells for proliferation
studies, with Bevacizumab alone (0.1, 0.5, 1.0, 1.5, 2 mg/ml)
or in combination with VEGF (50 ng/ml). After treatment,
cells were trypsined and centrifuged at 1,400× g for 5 min.
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3339The  cell  pellets  were  resuspended  in  0.5  ml  DMEM  and
counted. Counting was performed using the ViCell XR Cell
Viability  analyzer  (Beckman  Coulter,  Fullerton,  CA)
according to the manufacturer’s protocol.
Morphology—Before exposure of corneal endothelial
cells to Bevacizumab, cellular morphology was recorded by
bright-field microscopy. Subsequently, cell morphology was
assessed  with  an  Olympus  IX51  microscope  (Olympus,
Centre Valley, PA), 72 h after incubation with respective
concentrations of Bevacizumab (0.1, 0.5, 1, 1.5, 2 mg/ml),
VEGF (50 ng/ml) plus Bevacizumab and VEGF alone. Signs
of gross cellular damage, such as changes in cytoplasmic and
nuclear morphology as a result of cytotoxicity were assessed,
in  both  control  and  treated  cells  [9].  Serum-starved  cells
served as controls.
Flow cytometry—Corneal endothelial cell cytotoxicity
was assessed by flow cytometric evaluation of annexin V
fluorescein  isothiocyanate  (FITC)-conjugate,  propidium
iodide (PI)- staining cells. For flow cytometry assays 100,000
cells/well were plated in 6-well plates. The cells were allowed
to  attach  for  24  h.  The  cells  were  treated  with  varying
concentrations of Bevacizumab (0.1, 0.5, 1.0, 1.5, 2 mg/ml)
and/or VEGF (50 ng/ml) and incubated for another 72 h. For
flow  cytometry  assays  using  PI  only,  the  cells  were
trypsinized and the pellet was resuspended in 70% ethanol
(Sigma-Aldrich)  solution  for  10  min  at  4  °C.  After
centrifugation and subsequent washes with Hank’s Balanced
Salt Solution (HBSS) (Invitrogen), the pellet was resuspended
in 10 µg/ml PI (Sigma-Aldrich) solution and incubated at
room temperature for 30 min in the dark [10]. Annexin V
labeling was used to detect apoptotic cells (Sigma-Aldrich).
After  centrifugation  and  subsequent  washes  with  Hank’s
Balanced Salt Solution (HBSS; Invitrogen), the pellet was
resuspended  in  1×  Binding  buffer  (Sigma-Aldrich).  Cells
incubated with annexin V-FITC and PI solution for 10 min at
room temperature were immediately analyzed. Cells, which
were early in the apoptotic process, stained with annexin V-
Figure 1. Effect of different concentrations of Bevacizumab on BCE
cell viability. Cell viability was determined by trypan blue exclusion
assays on an automated cell counter. Cell viability is unchanged
between Bevacizumab treated samples and controls. Viability rates
are expressed as percentages of control values. BEV (Bevacizumab).
FITC conjugate alone. By this method, necrotic (dead cells)
stain with both PI and annexin V-FITC. Stained cells were
analyzed  on  a  Beckman  Coulter  (Fullerton,  CA)  flow
cytometer using excitation at 488 nm and emission at 600 nm
for PI and 494 nm and 520 nm for annexin-FITC, respectively.
Ten thousand cells were counted per sample, and the data was
processed using standard software (Beckman Coulter).
Cell growth assays—For cell growth assays, cells were
plated  at  a  density  of  3,000  cells/well  in  96-well  plates.
Cellular  proliferation  was  assessed  according  to  the
manufacturer’s instruction with the 4-[3-(4-lodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolio]-1.3-benzene  disulfonate
(WST-1) kit (Roche, Mannheim, Germany). The colorimetric
assay is based on the cleavage of the tetrazolium salt WST-1
by  mitochondrial  dehydrogenases  in  viable  cells.  WST-1
solution (100 µl/well) was added to cells in 96-well plates
followed by incubation for 2 h at 37 °C. The plate was read
on a spectrophotometer at 440 nm with a reference wavelength
at 690 nm.
To  determine  the  safety  of  Bevacizumab  on  corneal
endothelial cells, we performed WST-1 proliferation assays.
Cells were treated with 0–100 ng/ml VEGF and / or different
doses of Bevacizumab (0.1, 0.5, 1, 1.5, 2 mg/ml) for 72 h. The
concentrations of Bevacizumab used were clinically relevant
[11].  VEGF  was  added  to  simulate  the  anterior  chamber
microenvironment that is often seen in neovascular glaucoma.
Statistical analysis: All experiments were done in at least
triplicates. Statistical analysis among treatment groups was
performed  with  ANOVA  (GraphPad,  La  Jolla,  CA).  For
proliferation and viability assays two-tailed t-test analysis was
used to determine p-values. For flow cytometry, results were
presented as means+/−standard error.
RESULTS
Cell cytotoxicity
Trypan  blue  exclusion  assay—In  controls,  corneal
endothelial cell viability was 98%, in Bevacizumab (0.1, 0.5,
1,  1.5,  2  mg/ml)  treated  cells  viability  was  98%,  97.3%,
98.1%, 94.8%, and 94.2%, respectively. The differences in
viability  were  non–significant  (p=0.4426,  0.4426,  0.4426,
0.839,  0.785,  respectively,  compared  to  controls)  and
Bevacizumab was not cytotoxic at the concentrations tested
(Figure 1). In VEGF (50 ng/ml)-treated cells viability was
98.3% (p=0.6479). In Bevacizumab (0.1, 0.5, 1, 1.5, 2 mg/ml)
and VEGF (50 ng/ml) treated samples the viability was 98.3%,
98.3%, 99%, 98%, 97% and 95.4%, respectively. VEGF (100
ng/ml) did not induce cytotoxicity (97% viability compared
to  98%  viability  in  controls).  VEGF  (50  ng/ml)  and
Bevacizumab treated cells at all concentrations tested (0.1,
0.5, 1, 1.5, 2 mg/ml) showed 95.4%–99% viability compared
to 98% viability in control groups (p=0.845, 0.99, 1, 0.40,
0.55, respectively, unpublished data).
Morphology—Bright-field  microscopy  of  polygonal
BCE cells in culture after 72 h did not show cell membrane
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3340Figure 2. Effect of Bevacizumab and VEGF on BCE cell morphology. A: Effect of different concentrations of Bevacizumab alone on BCE
cell morphology. B: Effect of different concentrations of Bevacizumab and VEGF on BCE cell morphology. Photomicrographs showing no
observable differences in morphology among different treatment groups and controls. Bright-field images were taken at a 20× magnification.
C: Serum-starved BCE cells showing small, picknotic nuclei, shrunken cytosol served as positive controls. BEV (Bevacizumab); V (vascular
endothelial growth factor; VEGF).
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3341Figure 3. Effect of Bevacizumab on BCE cell death as quantified by flow cytometry. A: Flow cytometry analysis of BCE cells treated with
Bevacizumab and/or VEGF. Cells were stained with propidium iodide (PI) before flow cytometry analysis. B: Viable percentage of gated
cells (Non-PI staining) from experiment shown in A. BEV (Bevacizumab); V (vascular endothelial growth factor; VEGF).
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3342damage,  a  shrunken  cytosol  or  nuclear  changes  in  either
controls,  VEGF,  Bevacizumab  alone  and  VEGF  plus
Bevacizumab-treated groups at all concentrations tested (0.1,
0.5, 1, 1.5, 2 mg/ml Bevacizumab; 50 ng/ml VEGF; Figure
2A,B). Serum- starved cells in contrast showed rounded cells
with picknotic nuclei and minimal cytosol (Figure 2C).
Flow cytometry—In flow cytometry experiments where
only PI staining was used, cytotoxicity of cells treated with
VEGF (50 ng/ml) was similar to controls (p=0.2909; Figure
3A,B). Bevacizumab did not lead to cytotoxicity in BCE cells
and PI incorporation in cells treated with Bevacizumab was
similar to controls (p=0.2752). The average percentages of
cells staining negatively for PI were 99.5% (controls), 99.6%
(50 ng/ml VEGF-treated cells), 99.5%, 99.6%, 99.5%, 99.7%,
99.8% (0.1 mg/ml, 0.5 mg/ml, 1 mg/ml, 1.5 mg/ml, 2 mg/ml
Bevacizumab-treated cells, respectively) and 99.9%, 99.4%,
99.5%,  99.6%,  99.7%  (50  ng/ml  VEGF  and  0.1  mg/ml,
0.5  mg/ml,  1  mg/ml,  1.5  mg/ml,  2  mg/ml  Bevacizumab-
treated cells, respectively; Figure 3A,B).
The percentages of cells staining positively for PI and
Annexin V, representing the population of cells which had
undergone necrosis were less than 1% (0.0%–0.3%) across
control  (0.0%),  VEGF  alone  (0.3%),  Bevacizumab  alone
(0.2%,  0.3%,  0.3%,  0.2%,  0.1%,  respectively)  and
Bevacizumab and VEGF (0.0%, 0.3%, 0.2%, 0.3%, 0.2%,
respectively) treatment groups (Figure 4).
To  further  determine  whether  Bevacizumab  produced
more subtle cytotoxicity in these cells, such as early apoptotic
changes,  cells  staining  with  annexin  V,  but  not  PI  were
analyzed. The percentages of control and Bevacizumab (0.1,
0.5,  1.0,  1.5,  2  mg/ml)-treated  cells  undergoing  early
apoptotic death are comparable (3.9% in controls compared
to 5.5%, 5.0%, 8.9%, 5.4%, 3.6% in Bevacizumab-treated
cells,  respectively).  The  percentages  of  VEGF  alone  and
Bevacizumab (0.1, 0.5, 1.0, 1.5, 2 mg/ml) and VEGF-treated
cells undergoing early apoptotic death were 5.5% in VEGF-
treated cells compared to 0.1%, 6.3%, 6.3%, 8.5%, 4.9% in
Bevacizumab-treated cells, respectively (Figure 4). Annexin
V,  PI-double  negative  (non-apoptotic)  cells  accounted  for
96% of controls, 94% of VEGF (50 ng/ml)-treated cells and
94.1%,  94.6%,  90.6%,  94.3%,  96.2%,  respectively,  of
Bevacizumab-treated  cells.  Similarly,  percentages  of
Bevacizumab (0.1, 0.5, 1, 1.5, 2 mg/ml) and VEGF-treated
annexin  V,  PI-double  negative  cells  were  99.8%,  93.1%,
93.2%,  91.1%,  94.8%,  respectively.  In  comparison,  cells
under serum-starved conditions (positive controls) showed
41.3%  AnnexinV/PI  -positive  staining  (Figure  4).  These
Figure 4. Effect of different concentrations of Bevacizumab on BCE cell death as quantified by flow cytometry. Flow cytometry analysis of
BCE cells treated with Bevacizumab and/or VEGF. Cells were stained with annexin V/propidium iodide (PI) before flow cytometry analysis.
Percentages of annexin V/PI negative (viable cells) are displayed in the lower left quadrant; annexin V negative/PI positive cells are displayed
in the upper left quadrant. Percentages of annexin V positive/PI positive (necrotic) cells are displayed in the upper right quadrant. Percentages
of annexin V positive/ PI negative (early apoptotic) are displayed in the lower right quadrant. Cells under serum-starved conditions were
considered as positive controls. BEV (Bevacizumab); V (vascular endothelial growth factor; VEGF).
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3343results are similar to those obtained through cell viability
analysis studies across control and treatment groups.
Cell  growth  assays—Proliferation  rates  of  treatment
groups were quantified as percentages of control proliferation
values (which were considered 100%). Proliferation rates in
VEGF-treated  samples  were  90.4%  of  those  in  control
samples  (VEGF  50  ng/ml;  p=0.32;  Figure  5A,B).  We
observed  an  increase  in  cell  numbers  (a  20%  increase
compared to controls) in response to VEGF at 100 ng/ml
(p=0.115; unpublished data).
Proliferation rates in Bevacizumab (0.1 mg/ml, 0.5 mg/
ml,  1  mg/ml)-treated  cells  were  85.5%,  84.7%,  95.7%,
respectively,  compared  to  control  proliferation  rates
(p=0.255, 0.318, 0.83, respectively). Bevacizumab (1.5 mg/
ml or 2 mg/ml) produced a significant 33% (p=0.005) or 47%
(p=0.001) decrease in cell proliferation rates compared to
controls. VEGF (50 ng/ml) and Bevacizumab (0.1, 0.5 mg/
ml)-treated cells showed decreased proliferation levels (88%,
82% compared to controls, respectively) as did Bevacizumab-
only treated cells at the same concentrations (p>0.05; Figure
5A,B). For VEGF and Bevacizumab (1.5, 2 mg/ml)-treated
samples there were significant decreased proliferation rates
compared  to  controls  (60%,  44%  compared  to  controls,
respectively; p=0.0114, 0.001). The decreases in proliferation
rates for both Bevacizumab (1.5, 2 mg/ml) and Bevacizumab
plus VEGF samples were comparable. Serum-starved cell
proliferation rates were 38.71% of control values. Positive
controls (serum-starved cells), showed a significant decrease
in cell numbers compared to controls (p<0.01).
DISCUSSION
Anti-VEGF treatment has revolutionized the management of
vasoproliferative  diseases  of  the  retina,  such  as  choroidal
neovascularization  associated  with  age  related  macular
degeneration,  proliferative  diabetic  retinopathy,  macular
edema  associated  with  central  retinal  vein  occlusion  and
neovascular glaucoma [12].
The  pharmacokinetics  of  Bevacizumab  after  an
intracameral  injection  are  not  well  known.  Intracameral
Bevacizumab  may  metabolize  faster  from  the  anterior
chamber than after an intravitreal injection and hence, may be
less  cytotoxic  to  the  corneal  endothelium.  However,  it  is
important to evaluate the effect of Bevacizumab on the corneal
endothelium, since corneal endothelial cells are likely to be
exposed to Bevacizumab after intracameral injection for a
considerable time period.
Corneal endothelial cell count declines steadily with age
[13]. Endothelial dystrophy, inflammation and trauma can
result in more serious cell loss. Lower endothelial cell count
leads to loss of corneal transparency and consecutive corneal
edema.  A  rapid  increase  in  the  aqueous  Bevacizumab
concentration is observed when Bevacizumab eye drops were
instilled in rabbit corneas, suggesting that Bevacizumab eye
drops can sufficiently penetrate the corneal stroma and the
anterior chamber [14]. In our study we examined the effect of
increasing concentrations of Bevacizumab on bovine corneal
endothelial  cells  in  the  presence  of  vascular  endothelial
growth factor.
In normal human corneas from donor eyes, VEGF is
expressed in corneal epithelial and endothelial cells, vascular
endothelial cells of the limbal vessels and keratinocytes [15].
VEGF  receptors  are  expressed  in  increased  densities  in
inflamed  and  vascularized  corneas  compared  to  normal
corneas  and  thus  may  play  an  important  role  in  corneal
neovascularization  [15].  The  surrounding  aqueous  humor
provides  the  cornea  with  nutrients  including  VEGF.
Intracameral  administration  of  Bevacizumab  neutralizes
VEGF available to the corneal endothelial cells. Bevacizumab
may be delivered topically, intracamerally or intravitreally for
treatment of ocular neovascularization [10,16]. Among the
different types of delivery, intracameral delivery is used less
frequently.  Topical  treatment  with  Bevacizumab  in  rabbit
eyes  leads  to  aqueous  accumulation  of  the  drug  [14].
Figure 5. Effect of VEGF and Bevacizumab on proliferation of BCE
cells.  A,  B:  Effect  of  different  concentrations  (0.1–2  mg/ml)  of
Bevacizumab  on  proliferation  of  BCE  cells.  Increasing
concentrations of Bevacizumab (1–2 mg/ml) produce a significant
decrease in cell proliferation rates compared to controls. VEGF does
not significantly change BCE proliferation rates as compared to
controls. Cell proliferation was determined by the WST-1 assay and
automated  cell  counting.  Proliferation  rates  are  expressed  as
percentages  of  control  values.  Proliferation  rates  under  serum-
starved  conditions  were  considered  as  positive  controls;  BEV
(Bevacizumab); V (vascular endothelial growth factor; VEGF). *
Indicates a significant decrease as compared to control (p<0.05).
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regression of iris vascularization [17,18,]. In a retrospective
study of 1,200 patients treated with intravitreal Bevacizumab,
corneal infiltrative keratitis and corneal stromal edema were
noted in 1.1% of patients [19].
Chalam et al. [11] demonstrated that Bevacizumab was
nontoxic to human corneal epithelial, corneal fibroblast and
human umbilical vascular endothelial cells at various doses.
Bevacizumab was not toxic to human corneal endothelial cells
at a concentration of 5 mg/ml [20]. Hosny et al. [21] showed
statistically significant high endothelial cell loss (3.4%) after
intracameral injection of Bevacizumab in vivo; however the
corneal transparency was not affected and remained clear.
Bevacizumab  has  been  employed  intracamerally  at  a
1.5 mg and 2.5 mg dose (0.06 ml or 0.1ml of a 25 mg/ml
solution,  respectively)  [22-24].  We  selected  our  doses  of
Bevacizumab at 0.1, 0.5, 1, 1.5 and 2 mg/ml to encompass two
log units above and two log units below the current clinical
range.  We  used  bovine  corneal  endothelial  cells  for  our
experiment which resemble human corneal endothelial cells.
These  results  are  consistent  with  the  non-cytotoxicity  of
Bevacizumab  on  other  cell  types  [11,25].  In  our  study,
Bevacizumab (1.5 mg/ml or 2 mg/ml) produced, respectively,
a  33%  (p=0.005)  or  47%  (p=0.001)  decrease  in  cell
proliferation  rates  compared  to  controls.  The  anti-
proliferative effects of Bevacizumab in BCE cells were dose-
dependent (1–2 mg/ml). Our study showed no cytotoxicity
with Bevacizumab (0.1, 0.5, 1, 1.5 and 2 mg/ml).
Cytotoxic compounds alter the morphology of corneal
endothelial cells. Pleomorphism and nuclear enlargement of
corneal endothelial cells are noted in response to increasing
doses  of  recombinant  tissue  plasminogen  activator  [9].
Bevacizumab did not alter the cellular morphology of corneal
endothelial  cells  despite  incubation  with  various
concentrations for 72 h. In contrast, serum-deprived BCE
cells, which served as positive controls, were rounder and
smaller.
Intracameral injections of Bevacizumab in rabbit eyes at
concentrations of 1.25 mg per 0.05 ml solution for 1 month
were not toxic to corneal endothelium [26]. Our results were
similar in a cell culture model.
In conclusion, Bevacizumab was not toxic to corneal
endothelial cells either alone or in combination with VEGF at
various clinically relevant doses.
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